Purpose: To determine the efficacy, tolerability, and safety of temozolomide in heavily pretreated patients with solid tumors and brain metastases.
Introduction
Brain metastases are estimated to occur in 20%-40% of cancer patients [1] , typically arising from primary cancers of the lung, breast, and skin in adults, and from sarcomas and germ-cell tumors in patients under 21 years of age. Over two thirds of patients with brain metastases suffer debilitating neurologic symptoms, including headache, focal weakness, cognitive dysfunction, and seizures. Further, once brain metastases have been diagnosed, the median survival is typically ^ 5 months [2, 3] .
Using recursive partitioning analysis (RPA), the Radiation Therapy Oncology Group has developed three prognostic classes to determine the appropriate treatment for patients with brain metastases [4] [5] [6] . These classes are based on Karnofsky performance status, primary tumor status, presence of extracranial metastases, and age, with class I patients (^65 years of age, Karnofsky score ^ 70, controlled primary disease, and no extracranial metastases) most likely to benefit from aggressive treatment strategies. With improvements in imaging and localization techniques, surgery or radiosurgery has become an accepted option for the treatment of patients with a single brain lesion [7] . Further, adjuvant therapy with whole-brain radiotherapy (WBRT) following surgery has been shown to decrease the rate of recurrence, increase survival, and improve the quality of life of these patients [8] [9] [10] . However, the treatment schedule must be carefully chosen to minimize the risk of long-term radiation-induced cognitive changes. Wholebrain radiotherapy represents the treatment of choice for patients with multiple brain metastases, and results in improvements in specific neurologic symptoms in up to 90% of patients [11] . However, WBRT is associated with a number of late complications, including brain atrophy, necrosis, endocrine dysfunction, and dementia [12, 13] .
The role of chemotherapy for the treatment of patients with brain metastases is not defined and remains somewhat controversial. Many clinical investigations have been discouraged by the assumption that the bloodbrain barrier (BBB) would prevent the passage of chemotherapy agents into the brain. However, data suggest that the BBB is disrupted when brain metastases are present, with reports showing that the concentration of chemotherapy drugs, including platinum, is similar in intracerebral and extracerebral tumors [14, 15] . Moreover, the data demonstrating the effectiveness of front-line chemotherapy in lung cancer patients with brain metastases are clearly inconsistent with the concept of the brain as a pharmacologic sanctuary for metastases. The activity of carboplatin and etoposide was studied in 30 patients with lung cancer (small-cell lung cancer [SCLC] , n -12; non-small-cell lung cancer [NSCLC] , n = 18) with brain metastases, in which an overall response rate of 33.3% was achieved [16] . However, grade 4 bone marrow toxicity was experienced by five (16.7%) patients. A regimen of cyclophosphamide, doxorubicin, vincristine, and etoposide was studied in patients (n = 14) with brain metastases from previously untreated SCLC and led to objective responses in the brain lesions of 9 of 11 (82%) evaluable patients [17] . However, toxicity was significant, with severe granulocytopenia and thrombocytopenia in 85% and 15% of patients, respectively. Six patients had major infectious complications, which resulted in septic deaths in two patients. In a recent study of 23 previously untreated patients with NSCLC and brain metastases, concomitant WBRT and chemotherapy with ifosfamide, vinorelbine, and cisplatin yielded an overall brain response rate of 56% [18] . However, all the patients suffered grade 4 neutropenia, and 14 experienced febrile episodes. In addition, a response rate of 59% (evaluated by computed tomography [CT] scan) in 22 breast cancer patients with brain metastases has been achieved with chemotherapy (cyclophosphamidemethotrexate-5-fluorouracil (5-FU) or 5-FU-doxorubicin-cyclophosphamide regimens) [19] . Clearly, chemotherapy is effective in patients with brain metastases from chemosensitive solid tumors (e.g., SCLC, breast), indicating that the BBB is at least partially disrupted when brain metastases are clinically detected. However, these treatment regimens are associated with severe adverse events that would preclude their use in the second-line setting in heavily pretreated patients.
Temozolomide is an oral, second-generation alkylating agent that has demonstrated activity in preclinical tumor models [20] [21] [22] . Temozolomide is rapidly absorbed following oral administration and undergoes spontaneous conversion at physiologic pH to the active metabolite (3-methyltriazen-l-yl) imidazole-4-carboxamide in the tissues [22, 23] . More importantly, temozolomide has a demonstrated ability to cross the BBB [24] .
The clinical efficacy and safety of temozolomide have been demonstrated in a number of phase II and III studies in patients with high-grade glioma and melanoma [25] [26] [27] [28] , including overall response rates of 46% and 62% achieved in patients with recurrent glioblastoma multiforme and astrocytoma, respectively. The most common dose-limiting toxicity observed was thrombocytopenia and/or neutropenia. In addition, myelosuppression was noncumulative. Non-hematologic toxicity included mild to moderate nausea, vomiting, headache, fatigue, and constipation.
In the present phase II study, the efficacy, safety, and tolerability of temozolomide were investigated in heavily pretreated patients with solid primary tumors and brain metastases.
Patients and methods

Patient characteristics
Patients with brain metastases from solid tumors with no other treatment options were registered at the Hellenic Cooperative Oncology Group office, with all inclusion and exclusion criteria reviewed by the principal investigator. Eligible patients were required to have histologically confirmed cancer with brain metastases assessed by magnetic resonance imaging (MRI) or CT. In addition, patients were required to be at least 18 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and have adequate hematologic, renal, and hepatic function. All patients gave informed written consent, according to institutional guidelines.
Patients who had previously undergone chemotherapy or radiotherapy to the brain within 4 weeks prior to study entry were excluded. In addition, patients who were human immunodeficiency virus-positive, pregnant or nursing, or had not fully recovered from toxicities from prior treatments (except alopecia), or who had any other uncontrolled life threatening systemic disease, were also excluded.
Study design
Baseline evaluations included a complete medical history, physical and neurologic examination, determination of ECOG performance status, hematology evaluation, and clinical chemistry assessments (including liver and renal function tests). Baseline tumor size was determined by gadolinium-enhanced MRI or contrast-enhanced CT of the brain. Hematologic tests were repeated on day 22 of each cycle. On the scheduled day of dosing, side effects were reported and baseline assessments repeated. Brain MRI or CT scans were required every 2 to 3 cycles and 4 weeks after the last course of treatment.
Treatment
Temozolomide was administered orally at 150 mg/nr/day for five consecutive days every four weeks. During each cycle, each daily dose was administered in the morning at approximately the same time. All doses were rounded up to the nearest 5 mg, and dose escalation was not allowed. If vomiting occurred during the course of treatment, no re-dosing was allowed before the next scheduled dose. Prophylactic antiemetics were administered to all patients. Corticosteroids were permitted during the study, but the dose was stabilized at least one week prior to study enrollment. Adverse events were determined according to the Common Toxicity Criteria, and if grade 2-4 events had not resolved to at least grade I before the next course, treatment was delayed. Treatment continued until disease progression or unacceptable toxicity.
Assessment of efficacy
The primary end points were objective response rate, time to progression, and overall survival. The secondary end points were safety and tolerability, and clinical neurologic performance status. Objective responses in measurable brain lesions (both diameters ^ 1 cm) were based on changes in tumor volume on radiologic studies compared with baseline scans. Tumor responses were graded according to the World Health Organization criteria [29] . Responses in lesions that were nonmeasurable (both diameters were not ^ 1 cm) were scored according to a six-point grading system (no evidence of tumor, definitely better, possibly better, unchanged, possibly progressed, definitely progressed). These lesions were excluded from the calculations of objective response. All CT or MRI scans were assessed by two independent radiologists at the Hellenic Cooperative Oncology Group office. The clinical neurologic performance status was based on symptoms described by the patient and on a clinical examination, and was graded as definitely better, possibly better, unchanged, possibly worse, or definitely worse. Patients were accrued in this study based on Simon's two-stage minimax design [30] , in order to optimize the probability of observing a real response and to minimize the probability of testing an ineffective drug.
Results
Patient characteristics
Patient demographics and baseline disease characteristics are shown in Table 1 . A total of 28 patients with various solid tumors were entered into the study from May 1998 to October 1999, including 12 patients with NSCLC, 5 patients with SCLC, 4 patients with breast cancer, 2 patients with melanoma, and 5 patients with other tumors. All patients (n = 28) had brain metastases, with the majority of patients having at least one additional site of metastatic spread ( Table 1 ). The median age was 56 years, and approximately half of the patients (13 of 28 patients) had an ECOG performance status of 2 or 3. Sixteen patients had ^ 2 metastatic sites, and the majority had been heavily pretreated, including twentythree patients who had received WBRT and twenty-two patients who had received one or more chemotherapy regimens.
Of the 28 patients registered, 1 patient with NSCLC signed the consent form but then refused to participate. A total of 27 patients received treatment and were therefore initially assessable for response and safety.
Efficacy of temozolomicle
Of the 24 evaluable patients, 14 (58%) died or had clear clinical progression after a median of 45.5 days (range 13-70 days) after the initiation of treatment. One further patient discontinued treatment after the first cycle due to emetic toxicity. There was one (4%) patient with a partial response (PR) in the evaluable population, with four (17%) patients with stable disease. Of the three patients with nonmeasurable disease that were excluded from the efficacy analysis, two patients had definitely progressed and one patient was classified as having possibly progressed following temozolomide treatment. Within the entire population of 27 treated patients (with measurable and nonmeasurable lesions), overall median survival was 4.5 months (range 0.5-15.5 months) and median time to progression was 3 months (range 0.4-12.8 months). The PR was achieved in a 44-year-old man, diagnosed in June 1997 with a highly differentiated adenocarcinoma of the left lung, with left pleural and pericardial effusions and multiple brain metastases. The patient received external beam WBRT (daily dose 300 cGy; cumulative dose 3600 cGy), one cycle of systemic chemotherapy with paclitaxel and carboplatin, and seven cycles of a mitomycin-cisplatin-vinblastine combination regimen. A PR was achieved at the primary tumor site and complete response demonstrated in the pleural and pericardial effusions. Following disease progression at both the primary site and in brain metastases, the patient received 11 cycles of temozolomide and achieved a gradual clinical and imaging improvement in both brain and lungs. The patient lived for 15.5 months after entering into the study and 28 months after his diagnosis. His response had a duration of 11.4 months. In June 1999, he progressed and went off study.
Two patients with SCLC who had both received prior chemotherapy and WBRT achieved disease stabilization under temozolomide therapy for 8.2 and 4.3 months, respectively. Disease stabilization was observed in two other patients. One patient with vaginal cancer and brain metastases received one chemotherapy regimen (platinum, paclitaxel, and 5-FU) and WBRT, but unfortunately the disease progressed. Subsequently, she remained stable for 4.1 months with temozolomide treatment. The second patient received interferon therapy for melanoma, and subsequently developed a single pulmonary lesion and multiple brain metastases. A complete response was achieved in the pulmonary lesion and disease stabilization in the brain following temozolomide therapy. However, within 1 month, the disease in the brain rapidly progressed.
A total of 74 cycles of temozolomide were administered; the majority of patients received «S 3 cycles. Eight patients received only one cycle because of rapid disease progression, and one patient discontinued treatment after one cycle because of severe nausea and vomiting. The major reasons for discontinuation of temozolomide were disease progression (20 patients, 71%) and death (6 patients, 21%). Improvements (denned as possibly or definitely better) in clinical neurologic symptoms were achieved in 10 (37%) patients, with a further 2 (7%) patients reporting unchanged neurologic status (Table 2 ). In addition, three patients had improvements in ECOG performance scores, including one patient who improved from a score of 2 (unable to work) to a score of 0 (fully active, predisease status).
Safety of temozolomide
Treatment with temozolomide was generally well tolerated (Table 3) , and adverse events were self-limited. Grade 3 headache was reported in three patients, grade 3 nausea in four patients, and grade 3 vomiting in four patients. All other adverse events were grade 1-2, and no grade 4 adverse events were observed.
Discussion
The role of chemotherapy for the treatment of patients with solid tumors and brain metastases remains controversial. Indeed, many clinical investigations have been discouraged by the concern that chemotherapy drugs that would have efficacy against the primary tumor (e.g., lung carcinoma), such as vincristine, doxorubicin, and carboplatin, would not cross the BBB, and therefore would not be active against the metastatic disease [31] . However, data suggest that the BBB is disrupted when brain metastases are present and chemotherapy can be effective against brain metastases from chemosensitive solid tumors [17, 19, 32] . Unfortunately, the severe adverse events associated with these agents would be very difficult to tolerate for pretreated patients who had already received radiation and multiple regimens of myelosuppressive chemotherapy.
In the present study, treatment with temozolomide achieved a partial response in one (4%) patient and disease stabilization in a further four (17%) patients. Importantly, these responses were achieved in a population of heavily pretreated patients. Twenty-three patients had received prior WBRT and twenty-two patients had received at least one prior chemotherapy regimen (Table 1 ). In addition, 13 patients had an ECOG performance score of 2-3, the majority of whom progressed quickly and died soon after entering into the study. Unfortunately, there are limited comparative data for the use of chemotherapy in pretreated patients with brain metastases. In a recent study of breast cancer patients with brain metastases, treatment with cisplatin and etoposide achieved responses in 21 of 56 (38%) patients [33] . Fifteen (27%) patients had received prior chemotherapy but, unfortunately, the response rate for this subgroup was not reported. Given the poor status and prior treatment history of these patients, temozolomide was safe and well tolerated ( Table 3 ). The majority of the adverse events were nonhematologic and grade 1 or 2 in severity, and all were self-limiting. Given the predictable myelosuppression observed in glioma patients treated with temozolomide (e.g., grade 3 or 4 thrombocytopenia [6%]) [27] , it was surprising to have no grade 3 or 4 hematologic events. This may be explained by fact that the majority (22 of 27) of patients in this study received three or fewer cycles of temozolomide.
In conclusion, temozolomide was safe and effective in the treatment of brain metastases in a population of heavily pretreated patients. The safety and tolerability of temozolomide permits this agent to be a potential treatment for patients not only with a Karnofsky performance status of ^70 ([RPA] class I), but also those with a performance status of <70 (RPA class III) [34] . In addition, the tolerability of temozolomide also permits use in combination with other cytotoxic agents or regimens. Cisplatin has been shown to reduce the activity of the DNA repair enzyme O 6 -aklylguanine-DNA alkyltransferase [35] , the same enzyme that mediates resistance to temozolomide treatment. Consequently, cisplatin might enhance the antitumor activity of temozolomide. Interestingly, cisplatin is an active cytotoxic drug in NSCLC, and a phase I study of a temozolomide and cisplatin combination has recently been reported and appears to be safe [36] . Clearly, this combination in NSCLC patients with brain metastases holds great potential.
